Two years in, the team at New York City-based Defiance ETFs
has crossed the $500 million AUM milestone.
| Matthew Ross Bielski|
Defiance ETFs, LLC
"Despite a global pandemic that has generated uncertainties across many sectors, we have continued to bring innovative first-to-market ETFs that are in high demand by both retail and institutional investors," Matt Bielski
, Defiance's CEO, stated
. They celebrated by ringing
the Nasdaq closing bell yesterday.
Earlier this month, the Defiance team unveiled their third ETF, the Defiance Nasdaq Junior Biotechnology ETF
(IBBJ). This ETF tracks small to mid-cap biotech companies, or those with a market capitalization of below $5 billion.
Defiance ETFs was founded in 2018
by Bielski after his previous experiences at ProShares, BlackRock, and Direxion. The firm crossed
the $100 million AUM line last year.
Stay ahead of the news ... Sign up for our email alerts now